

March 6, 2019



Exactus Places \$1 Million Purchase Order for CBD Products to Accelerate Near Term Growth

GLEN ALLEN, Va., March 06, 2019 (GLOBE NEWSWIRE) -- **Exactus Inc. (OTCQB: EXDI)**, a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced it had placed an initial purchase order with Ceed2Med, LLC. This first order consists of over 60 SKUs and represents the launch of our recently announced Master Product Development and Supply Agreement with Ceed2Med.

Bobby Yampolsky, founder and CEO of Ceed2Med, stated: "We are excited about the ambitious plans we have and the progress made by Exactus in identifying target markets for CBD. We see Exactus as a natural extension of our plans and the hard work we have done since the formation of Ceed2Med in 2018 and prior. Since 2014 our founders have worked hard to establish relationships with farms, extraction facilities, and other professionals to prepare industrial hemp biomass and turn it into finished products for consumers. Now that the Farm Bill has passed we are turning our attention to bringing these important products to market through our relationship with Exactus."

Bobby Yampolsky is a successful entrepreneur and the owner of ECJ Luxe Collections, based in Boca Raton, Florida. ECJ Luxe is a premier marketplace for high quality jewelry, timepieces, accessories, art and high-end cars.

Emiliano Aloï, who serves as senior advisor to Exactus from Ceed2Med, stated: "Exactus and Ceed2Med are developing a close link to prepare superior CBD products for the market. We have begun to work closely with Exactus' customers, launching a first line during February and are currently shipping samples of final product for approval. Our design and development team at Ceed2Med provided sample and design assistance. We anticipate that this first custom private label product will open doors to many more specialty stores through the customer's existing distribution network of over 1,000 locations. We are pleased to see the rapid development of the Exactus commercial operations and look forward to continuing to work closely with them as a vital partner."

Mr. Aloï continued: "Ceed2Med utilizes cGMP facilities in the United States, has expertise, resources, skills and experience in growing and processing active phyto-cannabinoid (CBD)

rich ingredients into isolates, distillates, water soluble, and proprietary formulations, including full-spectrum and broad-spectrum products. Because Ceed2Med owns farms and seeks to use premium genetics (seeds) we are better able to assure traceability from farm to the consumer. An important distinguishing component of the company's business plan is to provide a verifiable history and chain of custody from the seed through to the final consumer product which we expect to become the industry standard of performance and may become a future regulatory requirement."

Philip Young, CEO of Exactus said, "With an annual commitment of 2,500kg of final product, the Ceed2Med relationship gives Exactus the capacity to execute our business plan quickly in a way much of our competition can only envy since we have established a dedicated source of supply and development. This first order is one of many we have planned as we aggressively attack this exciting market opportunity."

For information about Exactus, their products and availability, please call 804-205-5036 or email, ir@exactusinc.com.

About Exactus:

[Exactus, Inc.](#), is a [healthcare company](#) pursuing opportunities in two distinct business segments, Hemp derived, [Cannabidiol](#), which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. That amount has not been shown to make a person feel "high." THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics. For more information about Exactus: www.exactusinc.com.

About Ceed2Med:

[Ceed2Med, LLC](#), is a hemp and hemp-derivative supply sourcing, production, distribution and development company that secures production of Industrial Hemp biomass and raw ingredients and invests in developing supply chain partners and distribution channels worldwide. The company operates and manufactures at cGMP facilities and processes raw material through a number of facilities in order to produce phyto-cannabinoid rich ingredients, including isolates, distillates, water soluble, and proprietary formulations. For more information about Ceed2Med: www.ceed2med.com.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2017 filed with the Securities and Exchange Commission (the "SEC") on April 2, 2018 and under the heading "Risk Factors" in our Current Report on Form 8-K filed with the SEC on January 14, 2019, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.

Safe Harbor - Forward Looking Statements

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.

For more information:

Company Contact:

Andrew Johnson
509.999.9696
ir@exactusinc.com



Source: Exactus, Inc.